ApoB may be a superior biomarker for assessing long‐term ASCVD risk, indicating that apoB‐containing lipoprotein particle number, rather than cholesterol content, is a more robust predictor of ASCVD risk. This evidence concerns the gene APOB and atherosclerosis.